Method for treating lupus by administering an anti-IL-12 antibody
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
1. A method for reducing symptoms of systemic lupus erythematosus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, to said animal.
2. The method according to claim 1 , wherein said effective amount is 0.001-50 mg/kilogram of said animal.
3. The method according to claim 1 , wherein said administering is subcutaneous.
4. The method according to claim 1 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist.
5. A method for reducing symptoms of systemic lupus erythematosus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain complementarity determining region CDR 1 of the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR3 of the amino acid sequence of SEQ ID NO: 3, a light chain CDR1 of the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 of the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 of the amino acid sequence of SEQ ID NO: 6, to said animal.
6. The method according to claim 5 , wherein said effective amount is 0.001-50 mg/kilogram of said animal.
7. The method according to claim 5 , wherein said administering is subcutaneous.
8. The method according to claim 5 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist.
9. A method for reducing symptoms of systemic lupus erythematosus in a human, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, to said human.
10. The method according to claim 9 , wherein said effective amount is 0.001-50 mg/kilogram of said human.
11. The method according to claim 9 , wherein said administering is subcutaneous.
12. The method according to claim 9 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist.
13. A method for reducing symptoms of systemic lupus erythematosus in a human, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain complementarity determining region CDR 1 of the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR3 of the amino acid sequence of SEQ ID NO: 3, a light chain CDR1 of the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 of the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 of the amino acid sequence of SEQ ID NO: 6, to said human.
14. The method according to claim 13 , wherein said effective amount is 0.001-50 mg/kilogram of said human.
15. The method according to claim 13 , wherein said administering is subcutaneous.
16. The method according to claim 13 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist.